Elegrobart

伊乐古拜单抗

Report date: 2025/11/10 17:51:54

Base Information

Drug NameElegrobart
Drug Alias NameVRDN-003
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsGraves Ophthalmopathy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesPolandGermany +[6] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesViridian Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesDRI Healthcare TrustViridian Therapeutics IncKissei Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsGraves Ophthalmopathy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A